Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Recruiting now · Phase 4

Conditions studied: Lu-177 PSMA

In brief

To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.

Key facts

Study ID

NCT07169825

Run by

M.D. Anderson Cancer Center

People needed

25

Starts

2026-03-30

Expected to finish

2028-09-01

Last updated by the study team

2026-08-04

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may not qualify if…

• Pluvicto therapy patients without renal or marrow function complications
• Participants who do not wish to be imaged multiple times as per the study protocol.
• Women and children since this is treatment for prostate cancer.

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.